english.prescrire.org > Spotlight > Archives : 2025 > Linzagolix (Yselty°) in uterine fibroids

Spotlight: Archives

Every month, the subjects in Prescrire’s Spotlight.

Linzagolix (Yselty°) in uterine fibroids

 Marketing Authorisations  Linzagolix, an oral GnRH antagonist, like relugolix, has been authorised in the European Union as a symptomatic treatment for uterine fibroids. To prevent the menopausal symptoms it induces, the company recommends adding an oestrogen-progestogen combination.
Full article available for download by subscribers

EDITORS' OPINION
Another cascade

When the pharmaceutical company MultiCombin suggested preventing the adverse effects of gizmoline by adding noxiozine, it then needed to prevent the adverse effects of noxiozine. The company soon found a solution: add a third drug! An unlikely scenario?

Full text available for download by subscribers

 ©Prescrire 1 May 2025

Source: "Linzagolix (Yselty°) in uterine fibroids" Prescrire Int 2025; 34 (270): 118-119. Subscribers only.

Filet

Enjoy full access to Prescrire International, and support independent information

 

Share
Share on  Facebook  
 
 
See also:

"Relugolix + estradiol +
norethisterone (Ryeqo°)
in uterine fibroids.
A risky hormone cocktail"
Prescrire Int 2023;
32 (244): 5-8.
Subscribers only